Protocol Ledger

NCT04300114 · Phase III · TERMINATED

A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Interventional Phase III clinical trial protocol NCT04300114 sponsored by Jiangsu HengRui Medicine Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-08-19 Enrollment: 5 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04300114
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)5 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04300114
Protocol FieldVerified Registry Value
NCT IdentifierNCT04300114
Consolidated Lead SponsorJiangsu HengRui Medicine Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment5 participants (ACTUAL)
Registered Start Date2020-08-19
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04300114
Hospital Research SiteLocationSite Profile
Anhui Provincial HospitalHefei, ChinaOpen Hospital Dossier ->
Beijing Cancer HospitalBeijing, ChinaOpen Hospital Dossier ->
Chinese PLA General HospitalBeijing, ChinaOpen Hospital Dossier ->
Peking Union Medical College HospitalBeijing, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI